EcoDrugPlus

Phosphodiesterase 3a

Ensembl ID : ENSVPAG00000002674
Gene Symbol: PDE3A
1 Cross references
272 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSVPAG00000008821
Gene Symbol: PDE3B
1 Cross references
217 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSVPAG00000007534
Gene Symbol: PDE4B
1 Cross references
292 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSVPAG00000006647
Gene Symbol: PDE4D
1 Cross references
244 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSVPAG00000011070
Gene Symbol: PDE5A
1 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSVPAG00000004188
Gene Symbol: PDE7A
1 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSVPAG00000003920
Gene Symbol: PDE7B
1 Cross references
189 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSVPAG00000010827
Gene Symbol: PIK3R1
1 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSVPAG00000011757
Gene Symbol: PIK3R3
1 Cross references
274 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSVPAG00000003627
Gene Symbol: PLA2G7
1 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSVPAG00000008970
Gene Symbol: PLA2G10
1 Cross references
249 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSVPAG00000009148
Gene Symbol: GART
1 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).